Adjuvant Therapy of Pancreatic Cancer
There is no clear consensus on what type of adjuvant therapy should be used for patients with pancreatic cancer. Chemoradiation is the favored treatment modality by many in the United States while gemcitabine based chemotherapy is favored in Europe. Both of these approaches have been shown by large prospective, randomized trials to improve disease free intervals and in some studies overall survival. This review is an update from the 2013 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium held in San Francisco, CA, USA. We present the summary of the findings from Abstracts #145 and #269 and discuss the potential impact on our clinical practice on this highly lethal cancer.
Image: Sign (Tufts Medical Center. Boston, MA, USA).
Neoptolemos JP, Stocken DD, Friess H, Bassi C et. al. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. N Engl J Med 2004;350:1200-10.
Oettle H, Post S, Neuhaus P, Gellert K et. al. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer. A Randomized Controlled Trial. JAMA. 2007;297:267-277
Neuhaus P, Riess H, Post S, Gellert K et. al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol 26: 2008 (May 20 suppl; abstr LBA4504).
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P. Adjuvant Chemotherapy with Fluorouracil plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. A Randomized Controlled Trial. JAMA. 0;0(10):1073-1081
Regine WF, Winter KA, Abrams RA, Safran H et al. Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A randomized Controlled Trial. JAMA. 2008;299(9):1019-1026.
Uesaka K, Fukutomi A, Boku N, Kanemoto H et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study). J Clin Oncol 30: 2012 (suppl 34; abstr 145).
Fan KY, Wild AT, Laheru DA, Pawlik TM. Phase II study of erlotinib combined with adjuvant chemoradiation and chemotherapy for resectable pancreatic cancer. J Clin Oncol 30: 2012 (suppl 34; abstr 269).
Saif MW, Syrigos KN, Katirtzoglou NA. S-1: a promising new oral fluoropyrimidine derivative. Expert Opin Investig Drugs. 2009 Mar; 18(3):335-48.
Ioka T, Ikeda M, Ohkawa S, Yanagimoto H et al. Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST study. J Clin Oncol 29: 2011 (suppl; abstr 4007)
Park SR, Park MS, Park YL, Kim NK et. al. CYP2A6 genetic polymorphism as a predictive marker for clinical outcomes in patients (pts) with metastastic gastric carcinoma (MGC) treated with S-1 plus docetaxel. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4633
Copyright (c) 2014 Chakra P Chaulagain, John Ng, Martin D Goodman, Muhammad Wasif Saif
This work is licensed under a Creative Commons Attribution 4.0 International License.As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.